# Context Therapeutics Inc.: financial statements, quarterly

CNTX · Nasdaq · CIK 1842952 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cntx.md) · [Financials](/companies/cntx/financials.md) · [Filings](/companies/cntx/filings.md) · [Insiders](/companies/cntx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cntx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating income | $m | [(6.2)](/filings/0001842952-24-000085.md) | [(6.9) d](/filings/0001842952-25-000028.md) | [(3.8)](/filings/0001842952-25-000048.md) | [(3.1)](/filings/0001842952-25-000081.md) | [(18.7)](/filings/0001628280-25-049533.md) | [(4.3) d](/filings/0001628280-26-020498.md) | [(5.5)](/filings/0001628280-26-031267.md) | [(9.8)](/filings/0001628280-26-053347.md) | [(10.6)](/filings/0001628280-25-049533.md) | [(13.8) d](/filings/0001628280-26-020498.md) | [(9.3)](/filings/0001628280-26-031267.md) | [(15.0)](/filings/0001628280-26-053347.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(5.9)](/filings/0001842952-24-000085.md) | [(6.8) d](/filings/0001842952-25-000028.md) | [(3.7)](/filings/0001628280-25-049533.md) | [(2.3)](/filings/0001628280-25-049533.md) | [(17.5)](/filings/0001628280-25-049533.md) | [(3.3) d](/filings/0001628280-26-020498.md) | [(4.6)](/filings/0001628280-26-053347.md) | [(8.8)](/filings/0001628280-26-053347.md) | [(9.7)](/filings/0001628280-25-049533.md) | [(13.0) d](/filings/0001628280-26-020498.md) | [(8.7)](/filings/0001628280-26-053347.md) | [(14.6)](/filings/0001628280-26-053347.md) |
| Diluted EPS | $ per share | [(0.37)](/filings/0001842952-24-000085.md) | not reported | [(0.23)](/filings/0001842952-25-000048.md) | [(0.04)](/filings/0001842952-25-000081.md) | [(0.22)](/filings/0001628280-25-049533.md) | not reported | [(0.05)](/filings/0001628280-26-031267.md) | [(0.09)](/filings/0001628280-26-053347.md) | [(0.10)](/filings/0001628280-25-049533.md) | not reported | [(0.09)](/filings/0001628280-26-031267.md) | [(0.15)](/filings/0001628280-26-053347.md) |
| Basic EPS | $ per share | [(0.37)](/filings/0001842952-24-000085.md) | not reported | [(0.23)](/filings/0001842952-25-000048.md) | [(0.04)](/filings/0001842952-25-000081.md) | [(0.22)](/filings/0001628280-25-049533.md) | not reported | [(0.05)](/filings/0001628280-26-031267.md) | [(0.09)](/filings/0001628280-26-053347.md) | [(0.10)](/filings/0001628280-25-049533.md) | not reported | [(0.09)](/filings/0001628280-26-031267.md) | [(0.15)](/filings/0001628280-26-053347.md) |

- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [21.7](/filings/0001842952-23-000085.md) | [14.4](/filings/0001842952-25-000028.md) | [10.1](/filings/0001842952-24-000035.md) | [102](/filings/0001842952-24-000065.md) | [84.8](/filings/0001842952-24-000085.md) | [94.4](/filings/0001628280-26-020498.md) | [89.4](/filings/0001842952-25-000048.md) | [83.5](/filings/0001842952-25-000081.md) | [76.9](/filings/0001628280-25-049533.md) | [66.0](/filings/0001628280-26-053347.md) | [54.5](/filings/0001628280-26-031267.md) | [43.0](/filings/0001628280-26-053347.md) |
| Current assets | $m | [23.0](/filings/0001842952-23-000085.md) | [16.0](/filings/0001842952-25-000028.md) | [11.0](/filings/0001842952-24-000035.md) | [103](/filings/0001842952-24-000065.md) | [86.1](/filings/0001842952-24-000085.md) | [97.9](/filings/0001628280-26-020498.md) | [92.7](/filings/0001842952-25-000048.md) | [86.9](/filings/0001842952-25-000081.md) | [79.1](/filings/0001628280-25-049533.md) | [68.4](/filings/0001628280-26-053347.md) | [58.5](/filings/0001628280-26-031267.md) | [45.8](/filings/0001628280-26-053347.md) |
| Total assets | $m | [23.0](/filings/0001842952-23-000085.md) | [16.1](/filings/0001842952-25-000028.md) | [11.1](/filings/0001842952-24-000035.md) | [103](/filings/0001842952-24-000065.md) | [86.3](/filings/0001842952-24-000085.md) | [98.1](/filings/0001628280-26-020498.md) | [93.0](/filings/0001842952-25-000048.md) | [87.2](/filings/0001842952-25-000081.md) | [79.2](/filings/0001628280-25-049533.md) | [68.5](/filings/0001628280-26-053347.md) | [58.9](/filings/0001628280-26-031267.md) | [46.1](/filings/0001628280-26-053347.md) |
| Current liabilities | $m | [4.6](/filings/0001842952-23-000085.md) | [4.2](/filings/0001842952-25-000028.md) | [2.6](/filings/0001842952-24-000035.md) | [1.6](/filings/0001842952-24-000065.md) | [2.3](/filings/0001842952-24-000085.md) | [2.7](/filings/0001628280-26-020498.md) | [1.9](/filings/0001842952-25-000048.md) | [4.6](/filings/0001842952-25-000081.md) | [6.0](/filings/0001628280-25-049533.md) | [8.0](/filings/0001628280-26-053347.md) | [6.5](/filings/0001628280-26-031267.md) | [7.9](/filings/0001628280-26-053347.md) |
| Total liabilities | $m | [4.6](/filings/0001842952-23-000085.md) | [4.2](/filings/0001842952-25-000028.md) | [2.6](/filings/0001842952-24-000035.md) | [1.6](/filings/0001842952-24-000065.md) | [2.5](/filings/0001842952-24-000085.md) | [2.9](/filings/0001628280-26-020498.md) | [2.0](/filings/0001842952-25-000048.md) | [4.6](/filings/0001842952-25-000081.md) | [6.1](/filings/0001628280-25-049533.md) | [8.0](/filings/0001628280-26-053347.md) | [6.7](/filings/0001628280-26-031267.md) | [8.0](/filings/0001628280-26-053347.md) |
| Shareholders' equity | $m | [18.4](/filings/0001842952-24-000085.md) | [11.9](/filings/0001628280-26-020498.md) | [8.4](/filings/0001628280-25-049533.md) | [101](/filings/0001628280-25-049533.md) | [83.9](/filings/0001628280-25-049533.md) | [95.3](/filings/0001628280-26-053347.md) | [91.0](/filings/0001628280-26-053347.md) | [82.5](/filings/0001628280-26-053347.md) | [73.2](/filings/0001628280-25-049533.md) | [60.5](/filings/0001628280-26-053347.md) | [52.2](/filings/0001628280-26-053347.md) | [38.2](/filings/0001628280-26-053347.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(3.5) d](/filings/0001842952-24-000085.md) | [(7.2) d](/filings/0001842952-25-000028.md) | [(4.4)](/filings/0001842952-25-000048.md) | [(3.4) d](/filings/0001842952-25-000081.md) | [(1.9) d](/filings/0001628280-25-049533.md) | [(4.9) d](/filings/0001628280-26-020498.md) | [(5.0)](/filings/0001628280-26-031267.md) | [(5.8) d](/filings/0001628280-26-053347.md) | [(6.6) d](/filings/0001628280-25-049533.md) | [(8.9) d](/filings/0001628280-26-020498.md) | [(11.4)](/filings/0001628280-26-031267.md) | [(7.0) d](/filings/0001628280-26-053347.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001842952-24-000085.md) | [0.0 d](/filings/0001842952-25-000028.md) | [0.0](/filings/0001842952-25-000048.md) | [0.0 d](/filings/0001842952-25-000081.md) | [0.0 d](/filings/0001628280-25-049533.md) | [0.0 d](/filings/0001628280-26-020498.md) | [0.0](/filings/0001628280-26-031267.md) | [0.0 d](/filings/0001628280-26-053347.md) | [0.0 d](/filings/0001628280-25-049533.md) | [0.0 d](/filings/0001628280-26-020498.md) | [0.0](/filings/0001628280-26-031267.md) | [0.0 d](/filings/0001628280-26-053347.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [16.0](/filings/0001842952-23-000085.md) | [16.0](/filings/0001842952-24-000035.md) | [16.0](/filings/0001842952-24-000065.md) | [16.0](/filings/0001842952-24-000085.md) | [16.0](/filings/0001842952-25-000048.md) | [55.0](/filings/0001842952-25-000081.md) | [80.5](/filings/0001628280-25-049533.md) | [95.2](/filings/0001628280-26-031267.md) | [95.2](/filings/0001628280-26-053347.md) | [95.2](/filings/0001628280-25-049533.md) | [95.2](/filings/0001628280-26-031267.md) | [95.2](/filings/0001628280-26-053347.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 91,879,177 at 2026-08-03, from the cover of the [10-Q filed 2026-08-05](/filings/0001628280-26-053347.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.